Ulcerative Colitis (UC) Completed Phase 3 Trials for Vedolizumab (DB09033)

Also known as: UC - Ulcerative Colitis / Colitis, Ulcerative (UC) / Ulcerative Colitis / Colitis, Ulcerative / Colitis,Ulcerative / Colitis Ulcerative / Proctocolitis, idiopathic / Idiopathic proctocolitis / UC / Ulcerative colitis, unspecified

IndicationStatusPhase
DBCOND0052192 (Ulcerative Colitis (UC))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02039505Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative ColitisTreatment
NCT00790933An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's DiseaseOther
NCT00783718Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative ColitisTreatment
NCT02497469An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative ColitisTreatment
NCT02611830Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative ColitisTreatment